MX2021014345A - Compuestos dirigidos a proteinas y composiciones farmaceuticas de los mismos, y sus aplicaciones terapeuticas. - Google Patents

Compuestos dirigidos a proteinas y composiciones farmaceuticas de los mismos, y sus aplicaciones terapeuticas.

Info

Publication number
MX2021014345A
MX2021014345A MX2021014345A MX2021014345A MX2021014345A MX 2021014345 A MX2021014345 A MX 2021014345A MX 2021014345 A MX2021014345 A MX 2021014345A MX 2021014345 A MX2021014345 A MX 2021014345A MX 2021014345 A MX2021014345 A MX 2021014345A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
therapeutic applications
compounds targeting
targeting proteins
protein
Prior art date
Application number
MX2021014345A
Other languages
English (en)
Inventor
Eduardo Torres
Kyle W H Chan
Paul E Erdman
Leah Fung
David Aaron Hecht
Aparajita Hoskote Chourasia
Imelda Lam
Frank Mercurio
Robert Sullivan
Original Assignee
Biotheryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotheryx Inc filed Critical Biotheryx Inc
Publication of MX2021014345A publication Critical patent/MX2021014345A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente descripción provee compuestos, por ejemplo, un compuesto de Fórmula (I), que modula la función de una proteína y/o restaura la homeostasis de la proteína. La descripción provee un método para modular una enfermedad, trastorno, afección o respuesta mediada por proteínas. Se proveen composiciones, incluso en combinación con otros agentes terapéuticos.
MX2021014345A 2019-05-24 2020-05-22 Compuestos dirigidos a proteinas y composiciones farmaceuticas de los mismos, y sus aplicaciones terapeuticas. MX2021014345A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962852844P 2019-05-24 2019-05-24
PCT/US2020/034264 WO2020242960A1 (en) 2019-05-24 2020-05-22 Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications

Publications (1)

Publication Number Publication Date
MX2021014345A true MX2021014345A (es) 2022-01-06

Family

ID=71092611

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014345A MX2021014345A (es) 2019-05-24 2020-05-22 Compuestos dirigidos a proteinas y composiciones farmaceuticas de los mismos, y sus aplicaciones terapeuticas.

Country Status (14)

Country Link
US (2) US11345712B2 (es)
EP (1) EP3976623A1 (es)
JP (1) JP2022533260A (es)
KR (1) KR20220023343A (es)
CN (1) CN114502543A (es)
AU (1) AU2020283744A1 (es)
CA (1) CA3140078C (es)
EA (1) EA202192910A1 (es)
IL (1) IL288204A (es)
MX (1) MX2021014345A (es)
SG (1) SG11202112355VA (es)
TW (1) TW202110818A (es)
WO (1) WO2020242960A1 (es)
ZA (1) ZA202109124B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513515B2 (en) * 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
IL293481A (en) * 2019-12-06 2022-08-01 Celgene Corp Processes for the preparation of 2-(4-chlorophenyl)-n-((2-(2,6-dioxypyridin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
CA3161497A1 (en) * 2019-12-12 2021-06-17 Kyle W.H. Chan Pde4 inhibitors, pharmaceutical compositions, and therapeutic applications
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
US20240050428A1 (en) * 2020-10-07 2024-02-15 Cullgen (Shanghai), Inc. Compounds and methods of treating cancers
TW202231269A (zh) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras蛋白降解劑、其醫藥組合物及其治療應用
WO2022132603A1 (en) 2020-12-14 2022-06-23 Biotheryx, Inc. Pde4 degraders, pharmaceutical compositions, and therapeutic applications
WO2022152821A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
AU2022253450A1 (en) * 2021-04-05 2023-11-16 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
CN117561244A (zh) * 2021-06-08 2024-02-13 杭州格博生物医药有限公司 异吲哚啉酮类化合物及其用途
WO2023274246A1 (zh) * 2021-06-28 2023-01-05 成都分迪药业有限公司 酰胺类化合物及其用途
WO2023001028A1 (zh) * 2021-07-19 2023-01-26 南京明德新药研发有限公司 杂芳-3-哌啶二酮类化合物及其应用
WO2023069708A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and uses thereof
WO2023070120A1 (en) * 2021-10-22 2023-04-27 Biotheryx, Inc. Ketoamides for treating malignancy
WO2023069731A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
CA3239528A1 (en) * 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2023233730A1 (en) 2022-03-17 2024-09-26 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN114835680A (zh) * 2022-04-29 2022-08-02 成都分迪药业有限公司 卤素取代异吲哚啉化合物及其应用
CN115636811A (zh) * 2022-08-17 2023-01-24 成都分迪药业有限公司 异吲哚啉苄胺衍生物的合成方法
US20240158370A1 (en) * 2022-09-09 2024-05-16 Innovo Therapeutics, Inc. CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2024167423A1 (en) * 2023-02-07 2024-08-15 Captor Therapeutics S.A. Gspt1 degrader compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
WO2017120422A1 (en) * 2016-01-08 2017-07-13 Celgene Corporation Antiproliferative compounds, and their pharmaceutical compositions and uses
CN108069959A (zh) * 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用
JP2020504711A (ja) 2016-12-21 2020-02-13 バイオセリックス, インコーポレイテッド タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用
US10406165B2 (en) 2017-03-14 2019-09-10 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
WO2019241274A1 (en) 2018-06-13 2019-12-19 Biotheryx, Inc. Aminoamide compounds
US11236103B2 (en) * 2018-07-27 2022-02-01 Biotheryx, Inc. Bifunctional compounds

Also Published As

Publication number Publication date
AU2020283744A1 (en) 2021-12-09
US20220298172A1 (en) 2022-09-22
ZA202109124B (en) 2023-10-25
EA202192910A1 (ru) 2022-03-18
EP3976623A1 (en) 2022-04-06
IL288204A (en) 2022-01-01
WO2020242960A1 (en) 2020-12-03
SG11202112355VA (en) 2021-12-30
CA3140078A1 (en) 2020-12-03
KR20220023343A (ko) 2022-03-02
US11345712B2 (en) 2022-05-31
CA3140078C (en) 2023-11-28
TW202110818A (zh) 2021-03-16
JP2022533260A (ja) 2022-07-21
US20200369679A1 (en) 2020-11-26
CN114502543A (zh) 2022-05-13

Similar Documents

Publication Publication Date Title
ZA202109124B (en) Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications
AU2018338314A1 (en) Protein degraders and uses thereof
PH12021500014A1 (en) Fused ring compounds
MY191030A (en) Gdf15 fusion proteins and uses thereof
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
CL2020002012A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032)
CY1110530T1 (el) Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
WO2020132661A3 (en) Inhibitors of fibroblast activation protein
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
MX2020007628A (es) Composiciones y metodos de uso.
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
WO2018115017A3 (en) CRYSTALLINE STRUCTURE OF GREMLIN-1 AND ANTIBODY INHIBITOR
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
MX2018015353A (es) Usos terapeuticos de un inhibidor de c-raf.
EA202192925A1 (ru) Твердые формы ингибитора glyt1
WO2020132658A3 (en) Tubulysins and protein-tubulysin conjugates
CO2019012204A2 (es) Proteínas de unión al antígeno anti-jagged1
MX2019005212A (es) Vacuna de adn dirigida a wt1 para terapia de combinacion.
EA202090143A1 (ru) Фармацевтически приемлемые соли полипептидов и их применение
WO2020123330A3 (en) Anti-alpha-synuclein antibodies and uses thereof
BR112020004935A2 (pt) Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular